Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02Sep 2, 2026
MPS
What Will It Take for Organ-on-Chip Data to Replace Animal Studies?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-18Aug 31, 2026
Chinese Biopharma
Pharmaceutical Innovation in China Takes Center Stage
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-17Aug 25, 2026
Innovation Partner
CDMOs as Innovation Partners in R&D
Prateek Gupta, Ph.D.
OneSource Specialty Pharma
PAO-08-26-CL-05Aug 6, 2026
In Vivo Selection
Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-14Jul 13, 2026
Preclinical R&D
How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies
Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.
Lab Thread
PAO-06-26-CL-05Jun 29, 2026
Genome Engineering
Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-16Jun 29, 2026
Psych R&D
Rebuilding the Psychiatric Drug Discovery Pipeline
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-14May 13, 2026
Lab Software
Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research
Lab Thread
PR-05-26-01May 8, 2026
Proteomics
RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment
RareCyte
PR-04-26-09Apr 20, 2026
Intercellular
Transferring Cytoplasmic Contents and Organelles Between Living Cells
Waseda University
PR-04-26-06Apr 3, 2026
Laboratory Data
Can Lab Management Software Help Solve the Reproducibility Crisis?
Sophie Lutter, Ph.D.
Lab Thread
PAO-034-26-CL-01Apr 1, 2026
Drug Delivery
Duration Is the New Potency: Why Exposure Control Is Replacing Peak Concentration
David Alvaro, Ph.D.
Pharma's Almanac
PAO-01-26-NI-16Jan 16, 2026
R&D Funding
When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy
David Alvaro, Ph.D.; Daniel Smith, Ph.D.
Pharma's Almanac
PAO-01-26-NI-07Jan 9, 2026
EU Overhaul
Europe’s Pharma Overhaul: How the New Incentive Model Will Reshape Global Innovation Strategy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-25-NI-06Nov 18, 2025
Organoids
How Organoids Are Continuing to Transform the Path from Bench to Bedside
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-25-NI-05Oct 16, 2025
Lab Technology
Verder Scientific's Multi-Brand Approach to Pharmaceutical Innovation
Julia Buckley
Verder Scientific
PAO-04-24-PHEX-23Jun 16, 2025
R&D Funding
Cutting Public R&D Would Slash U.S. GDP, Innovation, and Industry Growth, New Report Warns
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-25-NI-15Apr 30, 2025
NIH
The White House’s War on the NIH and the Disasters Ahead
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-25-NI-05Mar 24, 2025
Magnetogenetics
Magnetogenetics and the Future of Remote Biological Control
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-25-NI-04Mar 17, 2025